Buradasınız

Anasayfa » Content

Hemodiyaliz Yetersizliğine Bağlı Bir Pansitopeni Olgusu (Olgu Sunumu)

A Case With Pancytopenia Due to Hemodialysis Inadequacy (Case Report)

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Hemodialysis inadequacy affects not only morbidity and mortality of the dialysis patients, but it can also reduce the effectivity of therapies such as rHuEPO. Hemodialysis inadequacy and erythro-poietin ineffectivity are the essential problems of the physicians who deal with patients who have end stage renal failure, and they reduce treatment success. We report a rarely seen case who has pancytopenia because of hemodialysis inadequacy and/or rHuEPO ineffectivity.
Bookmark/Search this post with
Abstract (Original Language): 
Yetersiz diyaliz hastaların morbidite ve mortalitelerini etkilemekle kalmaz, beraberinde eritropoetin (rHuEpo) gibi birtakım tedavilerin de etkinliklerinin azalmasına sebep olabilir. Hemodiyaliz yetersizliği ve rHuEpo etkisizliği son dönem böbrek yetmezliği hastaları ile uğraşan hekimlerin bu alanlardaki başarı şanslarını azaltan başlıca etmenlerdendir. Hemodiyaliz ve/veya rHuEpo etkisizliği sonucu nadir görülebilen bir antite olan pansitopenili bir olguyu sunmayı uygun gördük.
FULL TEXT (PDF): 
PDF icon pdf_tndt_528.pdf
  • 2
93-96
  • Turkish

REFERENCES

References: 

1. Lazarus JM, Denker BM, Owen WF. Hemodialysis. In: Brenner BM (Ed), The Kidney. W.B. Saundres Company, Philadelphia, 1996:2424-2506.
2. Depner TA. Hemodialysis therapy. In: Massry SG, Glassock RJ (Eds), Textbook of Nephrology. Lippincott Williams and Wilkins, Philadelphia, 2001:1474-1526.
3. Gotch FA, Sargent JA. A mechanistic analysis of the National
Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-534.
4. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and asso¬ciated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-619.
5. Van Wyck DB. Hematopoietic system in uremia. In: Massry SG, Glassock RJ (Eds), Textbook of Nephrology. Lippincott
Williams and Wilkins, Philadelphia, 2001:1318-1329.
6. Delwiche F, Segal GM, Eschbach JW, Adamson JW. Hemato-poietic inhibitors in chronic renal failure: lack of in vitro spe¬cificity. Kidney Int 1986;29(3):641-648.
7. Fukushima Y, Fukuda M, Yoshida K, Yamaguchi A, Nakamo-to Y, Miura AB, Harada T, Tsuchida S. Serum Erythropoietin levels and inhibitors of erythropoiesis in patients with chro¬nic renal failure. Tohoku J Exp Med 1986;150(1):1-15.
8. Locatelli F, Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: What is the evidence base? Nephrol
Dial Transplant 2003;18(Suppl 8):viii 29-35.
9. Locatelli F. Optimizing dose and mode renal replacement therapy in anaemia management. Nephrol Dial Transplant 2002;17(Suppl 5):60-65.
10. Locatelli F, Del Vecchio L, Andrulli S. Dialysis: Its role in op¬timizing recombinant erythropoietin treatment. Nephrol Dial Transplant 2001;16(Suppl 7):29-35.
11. Zadrazil J, Bachlada P, Zahalkova J. Endogenous erythropo-ietin in patients on regular dialysis therapy. Vnikr Lek 1997;
43(10):649-54.
12. Nissenson AR. Erytropoietin overview-1993. Blood Purif
1994; 12(1):6-13.
13.
Şahi
n G, Soydan M. Kronik Böbrek Yetmezliği olan bir olguda pansitopeni nedeni: Hodgkin Lenfoma. 6. Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi 2005; 14(1):
45-47.

Thank you for copying data from http://www.arastirmax.com